GLP-2T
$130.00
For research use only. Tirzepatide is a synthetic dual-incretin peptide that acts as a co-agonist at both GLP-1 and GIP receptors, supplied for controlled laboratory research into metabolic signaling and endocrine regulation.
| FORM | PURITY |
|---|---|
| Lyophilized Powder | ≥99% (HPLC) |
GLP-2T For Laboratory Research
For In Vitro Research Use Only – Not for Human or Veterinary Application
Tirzepatide (GLP2-T) is a 39-amino acid synthetic peptide engineered as a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Its dual receptor activity makes it a compound of significant scientific interest in metabolic and endocrine research, where investigators study the downstream effects of incretin pathway co-activation on energy homeostasis, insulin secretion dynamics, and glucagon suppression.
Ongoing research focuses on Tirzepatide’s receptor binding kinetics, intracellular cAMP signaling cascade activation, and comparative potency at GLP-1R versus GIPR in both in vitro and ex vivo models. Its structural design — incorporating a C18 fatty diacid moiety for albumin binding — also makes it a subject of interest in peptide half-life and pharmacokinetic research.
Available in 10mg and 30mg vials. Tested in the USA for research and educational use.
Compound Details
| Full Name | Glucagon-Like Peptide-2 Receptor Agonist Analog |
| Receptor Target | GLP-2 Receptor (GLP-2R) |
| Vial Size | 10 mg / vial |
| Purity | ≥99% by HPLC |
| Appearance | White lyophilized powder |
| Solubility | Sterile bacteriostatic water |
| Storage | −20°C long-term; 4°C short-term (≤4 weeks lyophilized) |
| For Use | Laboratory and in vitro research purposes only |
Public Research References
Published Research References
- Drucker DJ. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nat Clin Pract Endocrinol Metab. 2005;1(1):22–31. PMID: 16929373 →
- Jeppesen PB, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473–1481. PubMed →
- Jasleen J, Ashley SW, Shimoda N, et al. Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Dig Dis Sci. 2000;45(9):1681–1687. PMID: 11052296 →
- Brubaker PL, Drucker DJ. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145(6):2653–2659. PubMed →
All references are provided for informational purposes. Products are for laboratory and scientific research purposes only. Not for human or animal consumption.
RESEARCH USE ONLY
All products sold by Hive Mind Peptides are intended strictly for laboratory and scientific research purposes only. These materials are not approved by the FDA and are not intended for human or veterinary use, clinical applications, diagnostic procedures, or therapeutic treatment of any kind. You must be 21 years of age or older to purchase.
By purchasing from Hive Mind Peptides, you confirm that you are a qualified researcher and that all materials will be handled solely within an appropriate research environment by personnel who understand the risks, limitations, and regulatory requirements associated with investigational compounds. Products must not be administered to humans or animals, represented as therapeutic agents, or used for any medical purpose.
Use of these materials is entirely at your own risk. Hive Mind Peptides assumes no liability for misuse, unsafe handling, improper application, or any regulatory or compliance issues arising from their use.
